Compare REXR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REXR | RGEN |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | United States | United States |
| Employees | 256 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 6.6B |
| IPO Year | N/A | 1995 |
| Metric | REXR | RGEN |
|---|---|---|
| Price | $33.70 | $126.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $41.00 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 2.5M | 922.4K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $0.09 | $14.30 |
| Revenue Next Year | $2.99 | $14.52 |
| P/E Ratio | ★ $43.28 | $843.80 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $32.14 | $100.99 |
| 52 Week High | $44.38 | $175.77 |
| Indicator | REXR | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 52.16 |
| Support Level | $33.60 | $121.25 |
| Resistance Level | $36.65 | $131.53 |
| Average True Range (ATR) | 0.80 | 5.76 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 43.02 | 46.13 |
Rexford Industrial Realty Inc is a real estate investment trust focused on owning, operating and acquiring industrial properties in Southern California infill markets. Its goal is to generate attractive risk-adjusted returns for the stockholders by providing superior access to industrial property investments and mortgage debt investments secured by industrial property in high-barrier Southern California infill markets. The company generates revenue from rental income derived from properties in its portfolio.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.